帕金森病的神经精神症状:进展与挑战
本文综述帕金森病神经精神症状的临床相关性、危险因素、神经生物学机制、评估工具与诊断标准、治疗证据及管理挑战,指出常规筛查不足、有效治疗选择有限,需进一步研究、提高认识和专科培训。
要点
- 神经精神症状在帕金森病病程中常见,可致残且临床意义与运动症状相当。
- 评估工具和正式诊断标准存在,但临床实践中很少常规筛查这些症状。
- 证据支持药物和非药物干预,但有效治疗选择相对较少。
核心结论
- 优化帕金森病神经精神症状的管理需要额外研究、提高认识、专科培训和开发创新照护模式。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 神经精神症状在帕金森病整个病程中常见,可致残且临床意义与运动症状相当。
- 其表现可与一般人群中的对应症状相似或不同。
- 危险因素包括人口学、临床和社会心理特征。
- 神经生物学基础复杂且尚未充分了解,最强证据涉及帕金森病相关神经病理改变、多巴胺能治疗相关机制及非帕金森病特异性效应。
- 评估工具和正式诊断标准存在,但临床实践中很少常规筛查。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In people with Parkinson's disease, neuropsychiatric signs and symptoms are common throughout the disease course. These symptoms can be disabling and as clinically relevant as motor symptoms, and their presentation can be similar to, or distinct from, their counterparts in the general population. Correlates and risk factors for developing neuropsychiatric signs and symptoms include demographic, clinical, and psychosocial characteristics. The underlying neurobiology of these presentations is complex and not well understood, with the strongest evidence for neuropathological changes associated with Parkinson's disease, mechanisms linked to dopaminergic therapy, and effects not specific to Parkinson's disease. Assessment instruments and formal diagnostic criteria exist, but there is little routine screening of these signs and symptoms in clinical practice. Mounting evidence supports a range of pharmacological and non-pharmacological interventions, but relatively few efficacious treatment options exist. Optimising the management of neuropsychiatric presentations in people with Parkinson's disease will require additional research, raised awareness, specialised training, and development of innovative models of care.
引用
- Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of Parkinson's disease: advances and challenges. Lancet Neurol. 2022. PMID: 34942142. doi:10.1016/S1474-4422(21)00330-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。